| Entry |
|
|---|
| Name |
Metformin (USAN/INN) |
|---|
| Formula |
C4H11N5
|
|---|
| Exact mass |
129.1014
|
|---|
| Mol weight |
129.1636
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Product (DG00113): | D00944<JP/US> |
| Product (mixture): | D09744<JP/US> D10586<US> D10587<US> D10752<US> D11067<US> |
|
|---|
| Efficacy |
Antidiabetic, Hypoglycemic, AMP kinase activator |
|---|
| Comment |
Biguanide
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04920 | Adipocytokine signaling pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BA Biguanides
A10BA02 Metformin
D04966 Metformin (USAN/INN)
Drug groups [BR:br08330]
Antidiabetic agent
DG01685 Insulin sensitizer
DG01684 Biguanide antidiabetic
DG00113 Metformin
D04966 Metformin
DG02044 Hypoglycemic agent
DG01684 Biguanide antidiabetic
DG00113 Metformin
D04966 Metformin
Target-based classification of drugs [BR:br08310]
Protein kinases
Serine/threonine kinases
CAMK group
AMPK (PRKAA)
D04966 Metformin (USAN/INN)
Drug groups [BR:br08330]
Antidiabetic agent
DG01685 Insulin sensitizer
DG01684 Biguanide antidiabetic
DG00113 Metformin
DG02044 Hypoglycemic agent
DG01684 Biguanide antidiabetic
DG00113 Metformin
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 9
1 C2c C 26.2960 -19.4016
2 N1b N 25.0898 -18.7081
3 N1c N 27.5139 -18.7081
4 N2a N 26.2960 -20.8058
5 C2c C 23.8721 -19.4016
6 C1a C 28.7260 -19.4016
7 C1a C 27.5139 -17.3038
8 N1a N 22.6600 -18.7081
9 N2a N 23.8721 -20.8058
BOND 8
1 1 2 1
2 1 3 1
3 1 4 2
4 2 5 1
5 3 6 1
6 3 7 1
7 5 8 1
8 5 9 2
|
|---|
